Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof

Abstract

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

What is claimed is: 
     
       1. A polymorph of compound: 
       
         
           
           
               
               
           
         
       
       wherein the polymorph is a hydrate; and wherein the polymorph exhibits an endotherm at about 283.7° C. as measured by differential scanning calorimetry. 
     
     
       2. The polymorph of a compound of  claim 1 , wherein the hydrate comprises up to about 17.2% water by weight. 
     
     
       3. The polymorph of a compound of  claim 1 , wherein the polymorph has a melting point of about 363° C. 
     
     
       4. A polymorph of compound: 
       
         
           
           
               
               
           
         
       
       wherein the polymorph is anhydrous; and wherein the polymorph exhibits an endotherm at about 282.7° C. as measured by differential scanning calorimetry. 
     
     
       5. The polymorph of a compound of  claim 4 , wherein the polymorph has a melting point of about 361° C.